AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...

President Donald Trump has signed an executive order imposing tariffs of up to 100% on imported brandname medicines, unless ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

For Lebrat, it goes back to simplicity of use: the synthetic persona leverages the data a team already has. Synthetic ...

The move comes as Novo Nordisk is experiencing a slowdown in sales growth for Wegovy, with its US revenues from the drug ...

AstraZeneca's Alexion unit is planning to file a new, long-acting follow-up to its Strensiq therapy for ultra-rare disease ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...